Drug comparison for her2-positive breast cancer after herceptin stops working
Treatments studied
Part of Cancer, Skin clinical trials.
This study compares a new antibody-drug conjugate (SHR-A1811) with a combination of two oral drugs (pyrotinib and capecitabine) for women with HER2-positive advanced breast cancer that has stopped responding to trastuzumab (Herceptin). It aims to see which treatment works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your breast cancer is HER2-positive (a protein that makes cancer grow)
- Your cancer has grown while on or shortly after trastuzumab (Herceptin) treatment
- You have at least one tumor that can be measured on a scan
- You are generally well enough to be up and about (ECOG score 0-2)
- You have not been treated with an antibody-drug conjugate (ADC) such as Enhertu
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different treatments for women with HER2-positive early breast cancer who had a complete response to initial therapy but still have cancer DNA in their blood. It aims to see which treatment is better at preventing the cancer from coming back.
This study tests a personalized treatment approach for HER2-positive breast cancer. It uses regular monitoring of your tumor to adjust the treatment before surgery, aiming to improve results. It might help you by tailoring therapy to your cancer's response.
This trial tests a combination of two drugs that target HER2-positive breast cancer: trastuzumab deruxtecan (currently the standard) plus a newer drug called pyrotinib. The goal is to see if combining these drugs helps people whose cancer has continued to grow despite taking trastuzumab deruxtecan alone.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) before surgery for women with early-stage HER2-positive breast cancer. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests a combination of two oral medications, capecitabine (a chemotherapy pill) and pyrotinib (a targeted therapy), for people with HER2-positive breast cancer that has spread and has already been treated with an antibody-drug conjugate (ADC). The goal is to see if this combination can help control the cancer.
This study tests whether giving two drugs (SHR-A1811 and pertuzumab) before surgery can shrink HER2-positive breast cancer tumors. It aims to see if this combination improves treatment outcomes for patients with stage II or III disease.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.